This table demonstrates the baseline demographics, clinical and diagnosis data for patients enrolled in our study, stratified by discharge outcomes. Outcome categories are defined as: - Favorab
IPT-weighted cumulative incidence and SHRs in the intention-to-treat analysis for factor Xa inhibitor cohort versus the dabigatran cohort during 5 years of follow-up.
